loader2
Partner With Us NRI

Cipla Ltd share Price Today

Company details

1,462.70
1,504.55
923.50
1,519.00
6M Return 17.12%
1Y Return 61.00%
Mkt Cap.(Cr) 120,229.06
Volume 4,389,470
Div Yield 0.57%
OI
-
OI Chg %
-
Volume 4,389,470

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
US drives growth, outlook for key geographies upbeat
About The Stock

    Cipla is a global pharma company with over 1,500+ products in 65 therapeutic categories, with over 50 dosage forms.

    • Indian branded formulations business accounts for ~45% of revenues and major therapies include respiratory, anti-infectives, gastro-intestinal among others

    • Cipla derives 26% of its export revenues from the US followed by 10% from South Africa, 17% from RoW markets and 2% from APIs

Q4FY23

    Cipla reported a mixed set of numbers wherein US sales and gross profit margins were above I-direct estimates but missed on the India front due to Covid base adjustment.

    • Revenue grew 9.1% YoY to ₹ 5,739 crore

    • EBITDA margins increased 620 bps YoY to 20.5%

    • Adjusted PAT increased 59.3% YoY to ~₹ 654 crore

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Cipla announced Q4FY24 & FY24 results:

FY24 Financial Highlights:
For the fiscal year 2024, Cipla's annual revenue surpassed Rs 25,000 crore with a growth of 14% YoY, while the Profit After Tax (PAT) soared by an impressive 47% YoY to Rs 4,106 crore.

Q4FY24 Financial Highlights:

For Q4FY24, Cipla's revenue was Rs 6,163 crore with a growth of 10% YoY, while the Profit After Tax (PAT) soared by an impressive 79% YoY to Rs 939 crore.

Umang Vohra MD and Global CEO, Cipla, said “I am pleased to share our performance for the year where we made substantial progress across our focused markets. In FY24, our revenues crossed the threshold of Rs 25,000 crore whereas operating margins significantly improved to cross Rs 6,000 crore for very first time, growing at healthy 14% on topline and 26% on profitability YoY. This was backed by One-India revenue breaching Rs 10,000 crore, North America revenue surpassing USD 900 million and South Africa reaching top spot in prescription market, with all three businesses growing in double digits over last year with improved profitability. As we enter into FY25, our focus will be on our priorities of market leading growth in our key markets, growing big brands bigger, investing in future pipeline as well as focusing on resolutions on regulatory front”.

Result PDF

View Other Company Results

Cipla Ltd shares SWOT Analysis

Strengths (12)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with high TTM EPS Growth
  • Effectively using its capital to generate profit - RoCE improving in last 2 years

Weakness (2)

  • Declining Revenue every quarter for the past 2 quarters
  • Declining profits every quarter for the past 2 quarters

Opportunity (1)

  • RSI indicating price strength

Threats (2)

  • Big Deal (Insider and SAST) sells last month greater than 1% of total shares
  • Increasing Trend in Non-Core Income

Resistance and support

R1 1,508.2
R2 1,527.3
R3 1,550.1
Pivot

1,485.47

S1 1,466.4
S2 1,443.6
S3 1,424.5
EMA SMA
1,418.0
1,414.9
1,386.3
1,311.1
1,408.9
1,428.8
1,406.7
1,310.5
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ICICI PRUDENTIAL MUTUAL FUND Bulk Purchase 2024-05-15 1345 5525999 NSE
SAMINA HAMIED Bulk Sell 2024-05-15 1345 8954750 NSE
SHIRIN HAMIED Bulk Sell 2024-05-15 1345 6363000 NSE
Name Category Shares
SOPHIE AHMED PROMOTER 5.71%
M K HAMIED PROMOTER 3.46%
SAMINA HAMIED PROMOTER 2.22%
RUMANA HAMIED PROMOTER 1.23%
SHIRIN HAMIED PROMOTER 0.79%
Yusuf Khwaja Hameid PROMOTER 18.68%
Kamil Hamied PROMOTER 1.36%

OUR RESEARCH VIEW

Investment recommendation
US drives growth, outlook for key geographies upbeat
Call Date
13 May 2023
Entry Price 935.00
Target Price 1,090.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Cipla Ltd Stocks COMPARISON

Financials( in Cr) Cipla Ltd Sun Pharmaceuticals Industries Ltd Zydus Lifesciences Ltd Divis Laboratories Ltd Dr Reddys Laboratories Ltd
Price 1,489.15 1,495.10 1,086.05 4,113.00 5,897.70
% Change 0.46 -2.87 0.50 1.34 0.42
Mcap Cr 120,229.06 358,724.58 109,282.04 109,187.40 98,384.25
Revenue TTM Cr 15,790.60 43,885.68 17,237.40 7,767.51 24,669.70
Net Profit TTM Cr 2,513.47 8,560.84 1,997.30 1,823.38 4,507.30
PE TTM 28.23 35.84 28.33 78.90 17.62
1 Year Return 61.00 59.49 114.53 25.97 32.31
ROCE 14.76 16.79 16.25 19.30 25.99
ROE 10.66 16.46 14.05 14.89 21.21
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 24,638.09 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 39,612.39 -26,051.38
LAST 3M 102,786.44 -35,737.56
LAST 6M 169,824.52 46,518.61
LAST 12M 263,183.06 125,165.94
Cipla Limited - Other General Purpose

May 23, 2024 l NSE Announcement

Cipla receives USFDA approval for Lanreotide Injection

May 22, 2024 l BSE Announcement

Cipla Limited - Updates

May 22, 2024 l NSE Announcement

Date Action Type Ratio
Jul 21, 2023 Dividend 425
Aug 08, 2022 Dividend 250

Cipla Ltd Information

Stock PE (TTM)
28.23
Promoter Holding
33.4%
Book Value
330.7729
ROCE
14.76%
ROE
10.66%
Description
  • Cipla Limited is a pharmaceutical company having a market capitalization of Rs. 73,307.57 crores as of 18th August 2021. The company was incorporated within the year 1935. It reported its consolidated revenue at Rs. 5,504.35 for the quarter ended June 2021. The Bombay Stock Exchange (BSE) and National Stock Exchange have assigned the number 500087 and scrip code CIPLA, respectively. As of 18th August 2021, the shares of Cipla were trading at Rs. 908.85.

    Cipla is headquartered in Mumbai and produces products for various therapeutic areas, including cardiology, children’s health, dermatology & cosmetology, diabetes, HIV/AIDS, infectious illnesses & critical care, malaria, and so on. The drug company primarily develops medicines to treat respiratory, disorders, arthritis, diabetes, weight control and depression, and other medical conditions. Cipla is the third-largest drug company within the country and is present in most countries within the European region, with DTMs in Germany, Norway, UK, and Spain. The company’s promoters hold a 36.72% stake of the total shareholding in the company in June 2021 as against 36.68% in June 2020 with zero pledge. However, the mutual funds holding has also decreased in the last 12 months, decreasing from 16.29% in June 2020 to 13.36% in June 2021, and over the last 3 months, it has decreased 1.28%.

    In June 2021, consolidated total revenue from operations grew 26.64% to Rs. 5,504.35 crores, against Rs. 4,346.16 crores within the corresponding quarter last year. The Indian major pharmaceutical has posted a 23.67% increase in the consolidated net profit of Rs. 714.72 crores, on strong sales performance during June 2021, it had posted a net profit of Rs. 577.91 Crores within the corresponding period of the previous fiscal. EBITDA rose 28% to Rs. 1,346 crores in June 2021, from Rs. 1,049 crores in June 2020. EBITDA margin improved 32 basis points to 24.5%, as against 24.1% in the year-ago period. EPS of the company was Rs. 8.86 as compared to Rs. 5.13 in March 2021. Cipla’s shares closed at 908.85 (NSE) on 18th August 2021 and have returned 18.83% over the last 12 months.

Registered Address

Cipla House Peninsula Buss Par, Ganpatrao Kadam Mg Lower Parel, Mumbai, Maharashtra, 400013

Tel : 91-22-24826000
Email : cosecretary:cipla.com, contactus:cipla.com
Website : http://www.cipla.com
Registrar

Karvy Computershare Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 500087
NSE Code : CIPLA
Book Closure Date (Month) :
BSE Group : A
ISIN : INE059A01026

FAQ’s on Cipla Ltd Shares

You can buy Cipla Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Cipla Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 23, 2024 03:59 PM the closing price of Cipla Ltd was Rs.1,489.15.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 23, 2024 03:59 PM, the market cap of Cipla Ltd stood at Rs. 120,229.06.

The latest PE ratio of Cipla Ltd as of May 23, 2024 03:59 PM is 28.23

The latest PB ratio of Cipla Ltd as of May 23, 2024 03:59 PM is 0.22

The 52-week high of Cipla Ltd share price is Rs. 1,519.00 while the 52-week low is Rs. 923.50

According to analyst recommendations, Cipla Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app